Table 1 Clinical and demographic characteristics of test and validation cohorts

Age^α

52 [44–59]

55 [45–60]

53 [51–54]

57 [53–61]

Black race

7 (58)

8 (67)

3 (38)

3 (38)

Male gender

12 (100)

12 (100)

3 (38)

7 (88)

Duration of HIV infection (years)^α

13 [11–20]

19 [13–22]

Viral load (copies/ml)

40 [10–80]

40 [40–40]

Viral load < 200 copies/ml

11 (92)

8 (100)

CD4 count (cells/μl)

955 [776–1142]

619 [430–734]

382 [285–495]

CD4 nadir (cells/μl)

639 [539–796]

166 [92–257]

82 [26–221]

CD4/CD8 ratio^α

1.4 [1.1–1.9]

0.73 [0.54–1.0]

0.41 [0.26–0.51]

ART use

12 (100)

8 (100)

Protease inhibitor use

7 (58)

6 (75)

HCV seropositive

1 (8)

1 (8)

0 (0)

0 (0)

Smoking

7 (58)

6 (50)

7 (88)

2 (25)

Cocaine use

6 (50)

6 (50)

4 (50)

4 (50)